Buy GHK-CU Copper Peptide 50mg

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973 by Loren Pickart. Its serum concentration declines sharply with age — from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60 — a temporal correlation that has driven significant research interest in its role as an endogenous regulator of tissue maintenance. The peptide's primary mechanism centres on its extraordinary ability to modulate gene expression: microarray studies have identified GHK-Cu as capable of upregulating or downregulating over 4,000 human genes, including resetting many age-associated gene expression changes toward a younger phenotype. This breadth of transcriptional influence stems from GHK-Cu's activation of multiple transcription factor networks simultaneously. At the cellular signalling level, GHK-Cu activates the Nrf2/ARE (Nuclear factor erythroid 2-related factor 2 / Antioxidant Response Element) pathway, one of the master regulatory systems for cellular antioxidant defence. Nrf2 activation induces expression of phase II detoxification enzymes (glutathione S-transferases, NQO1, heme oxygenase-1) and directly increases intracellular glutathione synthesis. This makes GHK-Cu a potent inducer of endogenous antioxidant capacity rather than merely an exogenous antioxidant itself — a mechanistically superior approach to combating oxidative stress in tissue. Simultaneously, GHK-Cu suppresses NF-κB signalling, reducing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Extracellular matrix remodelling is GHK-Cu's most visually apparent effect and the basis of its cosmetic dermatology applications. The peptide stimulates fibroblast production of collagen types I, III, and VII, elastin, fibronectin, and decorin, while simultaneously regulating MMP activity to ensure appropriate matrix turnover rather than net deposition or degradation. This bidirectional remodelling capacity — stimulating synthesis while maintaining catabolic balance — produces tighter, more organised connective tissue. GHK-Cu also activates TGF-β1 signalling in fibroblasts, synergising with its direct collagen-stimulating effects. In wounded skin, these actions translate to faster re-epithelialisation, reduced scar formation, and improved tensile strength of healed tissue. The copper ion (Cu²⁺) chelated within the peptide complex is integral to its biological activity rather than incidental. Copper is a cofactor for lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibres to form mechanically strong ECM; copper delivered via GHK is more bioavailable to target cells than inorganic copper salts. Copper also plays a role in superoxide dismutase (Cu/Zn-SOD) activity, contributing to the antioxidant effects. Beyond the skin, GHK-Cu has demonstrated neuroprotective activity — it increases NGF (nerve growth factor) and BDNF expression, promotes neurite outgrowth in culture, and has shown protective effects in models of neurodegeneration — suggesting applications well beyond dermatological research.

GHK-Cu at 50mg is appropriate for researchers investigating dermal wound healing, skin ageing biology, anti-fibrotic interventions, neuroprotection, or the transcriptional biology of ageing. The 50mg vial size reflects the relatively larger amounts typically used in topical formulation research compared to injectable peptide work. Researchers using GHK-Cu systemically (subcutaneously) will find 50mg provides substantial experimental capacity for multiple subjects or extended timelines. Sourcing quality is paramount. GHK-Cu should be provided as a characterised copper complex — not free peptide plus separate copper salt — with the coordination chemistry verified by the supplier. The correct form is the 1:1 peptide-to-copper complex; incorrect ratios produce different biological activity profiles. Molecular weight is 340.38 g/mol (anhydrous); verify this via mass spectrometry confirmation on the CoA. For topical research formulations, the peptide should be incorporated at 0.1–1% w/v in an appropriate vehicle (aqueous gel or liposomal carrier); higher concentrations do not linearly increase efficacy and may increase irritation. Lyophilised powder should be stored at −20°C with desiccant and protected from light. In rodent wound healing models, topical doses of 1–10 mcg per wound per application once or twice daily have produced significant effects. Systemic doses in the range of 1–3 mg/kg subcutaneously have been used in anti-ageing and neuroprotection studies. Researchers should expect measurable histological changes in collagen density and fibroblast activity within 2–3 weeks of consistent application in acute wound models. Anti-ageing transcriptomic effects require longer study windows (8–12 weeks) to manifest as measurable phenotypic changes. Given the long safety record of GHK-Cu in cosmetic and dermatological research contexts, it has one of the more reassuring safety profiles among injectable peptides.

GHK-Cu occupies a unique position among healing peptides because of its breadth of action — spanning ECM remodelling, antioxidant gene expression, inflammation, and neurotrophin regulation — and its long safety record in topical dermatology. Compared to BPC-157, GHK-Cu is less potent for acute musculoskeletal injury repair but superior for chronic tissue maintenance, anti-ageing applications, and systemic oxidative stress reduction. The two peptides address different temporal phases of tissue health: BPC-157 excels in acute injury contexts, while GHK-Cu is better suited to longer-term structural maintenance and reversal of age-related tissue decline. Within the Apollo peptide lineup, GHK-Cu is the natural companion to Epithalon and NAD+ in longevity protocols — each addressing a distinct aging axis. While Epithalon targets telomere length and NAD+ restores mitochondrial energy metabolism, GHK-Cu resets the gene expression landscape by modulating 4,000+ genes involved in collagen synthesis, antioxidant defense, and inflammatory control. In skin and connective tissue applications, GHK-Cu pairs well with SNAP-8 (expression line reduction via neuromuscular junction modulation) and BPC-157 (dermal angiogenesis and vascular support). GHK-Cu is best positioned as either a standalone anti-ageing research compound or a systemic adjunct in protocols where tissue quality maintenance alongside acute repair is desired.